Appearing as a significant breakthrough in the battle against obesity, the drug is generating considerable interest . This treatment combines the action of two established GLP-1 binding agonists, liraglutide, with an unique glucose-dependent peptide component. Initial study findings have demonstrated impressive body loss in individuals with exc… Read More